Evidence map›Paper›PMID 36478334›Full record

ArticleCancer science2023

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.

Kohei Shitara, Akihito Kawazoe, Akihiro Hirakawa, Yuka Nakanishi, Satomi Furuki, Musashi Fukuda, Yoko Ueno, Jeffrey Raizer, Ahsan Arozullah

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03528629 (A Phase 1 Open-label Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03528629 nacompletednot on this map

A Phase 1 Open-label Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

TypeinterventionalSponsorAstellas Pharma IncRan2018 to 2020Enrolled18ConditionsGastric Cancer, Gastro-esophageal Junction (GEJ) CancerArmsZolbetuximab
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Claudin 18.2 Targeting: A Pan-Cancer Perspective.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  5. Claudin 18.2 as a Biomarker for Imaging and Radiopharmaceutical Therapy in Gastric and Pancreatic Tumors.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  6. Advancements in targeted therapy for gastric cancer.Therapeutic advances in gastroenterology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  16. Article
  17. Article
  18. Claudin 18.2 as a novel therapeutic target.Nature reviews. Clinical oncology · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Kohei ShitaraDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.ORCID https://orcid.org/0000-0001-5196-3630
Akihito KawazoeDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Akihiro HirakawaTokyo Medical and Dental University, Tokyo, Japan.
Yuka NakanishiAstellas Pharma Inc., Tokyo, Japan.
Satomi FurukiAstellas Pharma Inc., Tokyo, Japan.
Musashi FukudaAstellas Pharma Inc., Tokyo, Japan.
Yoko UenoAstellas Pharma Inc., Tokyo, Japan.
Jeffrey RaizerAstellas Pharma Global Development, Inc., Northbrook, IL, USA.
Ahsan ArozullahAstellas Pharma Global Development, Inc., Northbrook, IL, USA.
Astellas Pharma (Japan) · JPAstellas Pharma (United States) · USNational Cancer Center Hospital East · JPTokyo Medical and Dental University · JP

Funding

Astellas Pharma Inc.
6 · The paper itself

Abstract

Zolbetuximab is a chimeric monoclonal antibody that targets claudin-18.2, a candidate biomarker in patients with advanced gastric/gastroesophageal cancer. This nonrandomized phase 1 study (NCT03528629) enrolled previously treated Japanese patients with claudin-18.2-positive locally advanced/metastatic gastric/gastroesophageal cancer in two parts: Safety (Arms A and B, n = 3 each) and Expansion (n = 12). Patients received intravenous zolbetuximab 800 mg/m

Indexed as

AdenocarcinomaEsophageal NeoplasmsStomach NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsClaudinsEast Asian PeopleEsophagogastric JunctionHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedClaudinsCLDN18 protein, humanzolbetuximabCLDN18.2 proteinclinical trial phase 1esophagogastric junctiongastric cancerzolbetuximab

Identifiers

PMID36478334
PMCPMC10067400
OpenAlexW4310950373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.